State Street’s Petros Pharmaceuticals PTPI Stock Holding History

State Street’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-182	Closed	-$23K	–	4887
2022 Q3	$23K	Hold	182	–	–	﹤0.01%	4808
2022 Q2	$37K	Hold	182	–	–	﹤0.01%	4783
2022 Q1	$71K	Buy	182 +4	+2%	+$1.69K	﹤0.01%	4727
2021 Q4	$149K	Buy	+178	New	+$104K	﹤0.01%	4462

Other funds holding PTPI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street's PTPI Position: Q4 2022 in Review

State Street sold out of Petros Pharmaceuticals (PTPI) in Q4 2022, closing a stake of 182 shares — an estimated $23K sold.

State Street first reported a position in PTPI in Q4 2021 and held it in 4 quarters. The position peaked at $149K in Q4 2021. 7 funds tracked by Wall St. Rank hold PTPI as of Q4 2022.

State Street reported no remaining Petros Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
State Street sold 182 Petros Pharmaceuticals shares in Q4 2022, an estimated $23K.
State Street first reported a position in Petros Pharmaceuticals in Q4 2021 and held it in 4 quarters.
State Street's Petros Pharmaceuticals position peaked at $149K in Q4 2021.
7 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.